TIGERMED (03347) announced its third-quarter results for 2025. The group recorded operating revenue of RMB5.026 billion in the first three quarters, representing a slight decrease of 0.82% year-on-year. Net profit attributable to shareholders rose 25.45% YoY to RMB1.02 billion, with basic earnings per share standing at RMB1.19.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.